Sana Biotechnology, Inc.
For the period ended Dec 31, 2024. Filed Mar 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 17, 2025
SANA$2.43-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Year Ended December 31, | ||||||
|---|---|---|---|---|---|---|
| 2024 · 2023 · 2022 | ||||||
| OPERATING ACTIVITIES: | ||||||
| Net loss | $(266,759) | $(283,255) | $(269,476) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
| Depreciation and impairment of long-lived assets | 17,391 | 24,557 | 15,625 | |||
| Stock-based compensation expense | 37,678 | 35,533 | 38,337 | |||
| Change in the estimated fair value of contingent consideration | (638) | (40,773) | (3,364) | |||
| Change in the estimated fair value of success payment liabilities | (8,243) | (8,208) | (81,518) | |||
| Non-cash expense for operating lease right-of-use assets | 9,681 | 13,265 | 12,106 | |||
| Other non-cash items, net | (11,078) | (13,312) | (9,302) | |||
| Changes in operating assets and liabilities: | ||||||
| Prepaid expenses and other assets | (3,513) | 8,143 | (5,988) | |||
| Operating lease right-of-use assets and liabilities | 9,341 | 10,959 | 1,562 | |||
| Accounts payable | 1,377 | 1,027 | 1,058 | |||
| Accrued expenses and other liabilities | (8,390) | (1,518) | 10,910 | |||
| Net cash used in operating activities | (223,153) | (253,582) | (290,050) | |||
| INVESTING ACTIVITIES: | ||||||
| Purchases of marketable securities | (226,064) | (157,744) | (78,688) | |||
| Proceeds from maturities of marketable securities | 276,947 | 349,788 | 310,126 | |||
| Purchases of property and equipment | (33,430) | (20,032) | (20,876) | |||
| Net cash provided by investing activities | 17,453 | 172,012 | 210,562 | |||
| FINANCING ACTIVITIES: | ||||||
| Proceeds from employee stock purchase plan and exercise of stock options | 11,005 | 4,626 | 4,312 | |||
| Proceeds from issuance of common stock from equity financings, net | 181,000 | 27,020 | 601 | |||
| Proceeds from tenant improvement loan, net | 7,744 | - | - | |||
| Net cash provided by financing activities | 199,749 | 31,646 | 4,913 | |||
| Net decrease in cash, cash equivalents, and restricted cash | (5,951) | (49,924) | (74,575) | |||
| Cash, cash equivalents, and restricted cash at beginning of period | 137,349 | 187,273 | 261,848 | |||
| Cash, cash equivalents, and restricted cash at end of period | $131,398 | $137,349 | $187,273 | |||
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||||||
| Cash and cash equivalents | $127,566 | $133,517 | $176,765 | |||
| Restricted cash | 3,832 | 3,832 | 6,100 | |||
| Long-term restricted cash | - | - | 4,408 | |||
| Total cash, cash equivalents, and restricted cash | $131,398 | $137,349 | $187,273 | |||
| SUPPLEMENTAL CASH FLOW INFORMATION: | ||||||
| Operating lease right-of-use assets obtained in exchange for lease obligations | $ | - | $8,984 | $21,073 | ||
| Purchases of property and equipment included in accounts payable and accrued liabilities | $ | - | $9,471 | $1,234 | ||
| Cash received for tenant improvement allowances | $7,509 | $12,547 | $2,014 | |||
| Derecognition of operating lease right-of-use asset for lease termination | $ | - | $(14,204) | $ | - | |
| Derecognition of operating lease right-of-use asset for lease modification | $(7,261) | $ | - | $(12,801) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.